Response to hepatitis B vaccine in HBsAg/anti-HBs negative and anti-HBc positive subjects.
Some anti-HBc positive subjects have been encountered in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs). The aim of this study was to evaluate the response to hepatitis B vaccination in such cases. A total of 33 subjects who were HBsAg and anti-HBs negative, anti-HBc positive, with normal serum aminotransferase levels were included in the study. A recombinant hepatitis B vaccine was administered to subjects. Sera samples were obtained 1 month after each vaccination and tested for anti-HBs. HBV DNA and HBeAg were not detected in any subject. Anti-HBs levels were measured above 10 > or = mIU/ml in 48.4% of cases after the first vaccination, 63.6% after the second vaccination and 90.9% after the third vaccination. Only 3 subjects (9.1%) lacked antibody response in spite of the 3-dose vaccination. In conclusion, preventive antibody levels were obtained after HBV vaccination in most of the HBsAg, anti-HBs negative, anti-HBc positive persons.
Sünbül
M
M
Department of Clinical Microbiology and Infectious Diseases, Ondokuz Mayis University, School of Medicine, Samsun, Turkey.
Leblebicioglu
H
H
Esen
S
S
Eroglu
C
C
Barut
S
S
D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008297:Male; D014611:Vaccination
D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines